A Phase 1, Open Label, Two-cohort, Non-randomized Fixed Sequence Study To Evaluate The Pharmacokinetic Drug Drug Interaction Between Pf-05221304 And Pf-06865571 In Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs PF 06865571 (Primary) ; PF 5221304 (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 16 Sep 2018 Status changed from recruiting to completed.
- 09 Jul 2018 Planned End Date changed from 13 Jul 2018 to 31 Aug 2018.
- 09 Jul 2018 Planned primary completion date changed from 13 Jun 2018 to 31 Jul 2018.